New RSV vaccine shows promise for seniors in major trial

NCT ID NCT04732871

Ongoing ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study tests an experimental RSV vaccine in adults aged 60 and older. The goal is to see how well the vaccine triggers the immune system, how safe it is, and how long protection lasts—up to 5 years. About 1,720 participants will receive one or more doses of the vaccine at different schedules.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Mobile, Alabama, 36608, United States
GSK Investigational Site

Phoenix, Arizona, 85020, United States
GSK Investigational Site

Riverside, California, 92503, United States
GSK Investigational Site

San Diego, California, 92103, United States
GSK Investigational Site

Coral Gables, Florida, 33134, United States
GSK Investigational Site

Fort Myers, Florida, 33912, United States
GSK Investigational Site

Sarasota, Florida, 34243, United States
GSK Investigational Site

The Villages, Florida, 32162, United States
GSK Investigational Site

Evansville, Indiana, 47714, United States
GSK Investigational Site

Wichita, Kansas, 67226, United States
GSK Investigational Site

Richfield, Minnesota, 55423, United States
GSK Investigational Site

Kansas City, Missouri, 64114, United States
GSK Investigational Site

Rochester, New York, 14609, United States
GSK Investigational Site

Mt. Pleasant, South Carolina, 29464, United States
GSK Investigational Site

Spartanburg, South Carolina, 29303, United States
GSK Investigational Site

San Antonio, Texas, 78229, United States
GSK Investigational Site

Norfolk, Virginia, 23502, United States
GSK Investigational Site

Wenatchee, Washington, 98801, United States
GSK Investigational Site

Espoo, 02230, Finland
GSK Investigational Site

Helsinki, 00100, Finland
GSK Investigational Site

Helsinki, 00930, Finland
GSK Investigational Site

Jarvenpaa, 04400, Finland
GSK Investigational Site

Kokkola, 67100, Finland
GSK Investigational Site

Oulu, 90220, Finland
GSK Investigational Site

Pori, 28100, Finland
GSK Investigational Site

Seinäjoki, 60100, Finland
GSK Investigational Site

Tampere, 33100, Finland
GSK Investigational Site

Turku, 20520, Finland
GSK Investigational Site

Essen, 45355, Germany
GSK Investigational Site

Essen, 45359, Germany
GSK Investigational Site

Goch, 47574, Germany
GSK Investigational Site

Hamburg, 20095, Germany
GSK Investigational Site

Mainz, 55116, Germany
GSK Investigational Site

München, 80339, Germany
GSK Investigational Site

Wallerfing, 94574, Germany
GSK Investigational Site

Würzburg, 97074, Germany
GSK Investigational Site

Fukuoka, 812-0025, Japan
GSK Investigational Site

Kumamoto, 861-4157, Japan
GSK Investigational Site

Tokyo, 160-0017, Japan
GSK Investigational Site

Changhua, 500, Taiwan
GSK Investigational Site

Taichung, 40447, Taiwan
GSK Investigational Site

Taichung, 407, Taiwan
GSK Investigational Site

Taipei, 100, Taiwan
GSK Investigational Site

Taipei, 104, Taiwan
GSK Investigational Site

Taipei, 112, Taiwan
GSK Investigational Site

Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.